Hercules Technology Growth Capital, Inc. provided its Q2 2014 portfolio update.

“Hercules’ origination activity was very strong during the second quarter, with new commitments totalling $198.6 million,” said Manuel A. Henriquez, co-founder, chairman and chief executive officer of Hercules. “We are very pleased to have been able to continue to deploy our excess liquidity to a number of promising and innovative companies which also meet our stringent credit requirements. With a strong cash position and selective investment process, we believe Hercules is well positioned to continue meeting the robust demand for capital.”

New Originations for Q2 2014:

As of June 26, 2014, Hercules has originated approximately $198.6 million of debt commitments to new and existing portfolio companies.

Hercules has made new commitments to the following eleven companies, assisting in their future growth and development.

• $35.0 million commitment to Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.
• $30.0 million commitment to Nanotherapeutics, Inc., an integrated biopharmaceutical company with a major focus on developing a diversified proprietary pipeline of products having both biodefense and medical applications.
• $25.5 million commitment to CareCloud Corporation, a provider of cloud-based practice management, electronic health record, and medical billing software and services.
• $22.5 million commitment to SkyCross, Inc., a global designer and manufacturer of advanced antenna and RF solutions.
• $15.0 million commitment to Celator Pharmaceuticals, Inc., a pharmaceutical company developing advanced therapies to treat cancer based identifying synergistic ratios of drugs that improve tumor cell kill.
• $15.0 million commitment to a software company that provides a commerce platform for retailers.
• $10.0 million commitment to Pong Research Corporation, which develops cases for the Apple iPhone, iPad, and Android smartphones to increase range and transmit stronger signal, while reducing exposure to wireless energy.
• $10.0 million commitment to Quanterix Corporation, a leader in high definition diagnostics, including its Simoa platform uses single molecule measurements to access previously undetectable proteins.
• $10.0 million commitment to a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of products for aesthetic medicine
• $4.5 million commitment to Poplicus, Inc., a software company that creates proprietary analytics from big data in the public sector.
• $4.0 million commitment to Zosano Pharma, Inc., a biopharmaceutical company developing a transdermal delivery technology for a broad range of therapeutic indications.

In addition, Hercules provided approximately $17.1 million of debt commitments and renewals to existing portfolio companies.

To view the entire press release, which includes principal repayments, liquidity events and IPO registrations, click here.

Hercules Technology Growth Capital, Inc. is the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science, and energy & renewable technology industries, at all stages of development. Since inception (December 2003), Hercules has committed more than $4.2 billion to over 270 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing.